2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-113972R
    Methyl mycophenolate (Standard) 31858-66-9
    Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis.
    Methyl mycophenolate (Standard)
  • HY-113986B
    (S)-Dexfadrostat 102676-86-8 98%
    (S)-Dexfadrostat ((S)-Fadrozole) is an aromatase inhibitor with an IC50 of 4.6 nM in human placental microsomes in vitro. (S)-Dexfadrostat can be used in the study of estrogen-dependent breast cancer, gynecomastia, and systemic lupus erythematosus.
    (S)-Dexfadrostat
  • HY-114080A
    Patamostat mesylate 114568-32-0 98%
    Patamostat (E-3123) mesylate is a potent protease inhibitor. Patamostat mesylate potently inhibits trypsin, plasmin and thrombin with IC50s of 39 nM, 950 nM and 1.9 μM, respectively. Patamostat mesylate may possess suppressing effects on pathogenesis and development of acute pancreatitis.
    Patamostat mesylate
  • HY-114080B
    Patamostat hydrochloride 3031765-17-7 98%
    Patamostat hydrochloride is a potent protease inhibitor. Patamostat hydrochloride potently inhibits trypsin, plasmin and thrombin with IC50s of 39 nM, 950 nM and 1.9 μM, respectively. Patamostat hydrochloride may possess suppressing effects on pathogenesis and development of acute pancreatitis.
    Patamostat hydrochloride
  • HY-114091A
    PF-00356231 766536-21-4 98%
    PF-00356231 hydrochloride is a specific, non-peptidic, non-zinc chelating ligand and inhibitor of matrix metalloproteinase MMP-12 (IC50=1.4 μM). PF-00356231 hydrochloride binds to MMP-12 and forms PF-00356231/MMP-12 complex. PF-00356231 hydrochloride shows potency against MMP-13, MMP-8, MMP-9, MMP-3 with IC50s of 0.00065, 1.7, 0.98, 0.39 μM, respectively.
    PF-00356231
  • HY-114097A
    CCR1 antagonist 11 hydrochloride 98%
    CCR1 antagonist 11 hydrochloride (A1B1) is an orally active CCR1 antagonist with the IC50 values of 0.03 μM, 0.58 μM and 0.32 μM for hCCR1, mCCR1 and rCCR1, respectively. CCR1 antagonist 11 hydrochloride can be used in the study of rheumatoid arthritis and other related inflammatory diseases.
    CCR1 antagonist 11 hydrochloride
  • HY-114806R
    Fenclofenac (Standard) 34645-84-6
    Fenclofenac (Standard) is the analytical standard of Fenclofenac. This product is intended for research and analytical applications. Fenclofenac is an orally active anti-inflammatory agent with a low ulcerogenic effect. Fenclofenac also exhibits antipyretic and analgesic activities, with an oral LD50 of 2280 mg/kg in rats. Fenclofenac can be utilized in inflammation research.
    Fenclofenac (Standard)
  • HY-114816S
    N-butyryl-L-Homoserine lactone-d5 2701379-46-4
    N-butyryl-L-Homoserine lactone-d5 is the deuterium labeled N-Butanoyl-L-homoserine lactone. N-Butanoyl-L-homoserine lactone (C4-HSL) is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). N-Butanoyl-L-homoserine lactone has antibacterial activity and is used in antibacterial biofilm. N-Butanoyl-L-homoserine lactone aptamers blocks qurom sensing and inhibits biofilm formation in Pseudomonas aeruginosa.
    N-butyryl-L-Homoserine lactone-d5
  • HY-114950R
    EXP3179 (Standard) 114798-36-6
    EXP3179 (Standard) is the analytical standard of EXP3179. This product is intended for research and analytical applications. EXP3179 is an important intermediate aldehyde metabolite of Losartan. EXP3179 has no AT1-R–blocking activity, but potently inhibits the expression of endothelial cyclooxygenase (COX)-2. EXP3179 exerts potent anti-inflammatory actions.
    EXP3179 (Standard)
  • HY-116282H
    Dextran sulfate sodium salt (MW 9000-20000) 9011-18-1 98%
    Dextran sulfate sodium salt (DSS) (MW 9000-20000) is a polymer of dehydrated glucose with a molecular weight of approximately 9000-20000. Dextran sulfate sodium salt with different molecular weights exhibits different biological activities. Dextran sulfate sodium salt (MW 9000-20000) is a biocompatible and biodegradable biochemical reagent and can be used for pharmaceutical and biomedical applications.
    Dextran sulfate sodium salt (MW 9000-20000)
  • HY-116282I
    Dextran sulfate sodium salt (MW>500000) 9011-18-1 98%
    Dextran sulfate sodium salt (MW>500000) (DSS (MW>500000)) is a negatively charged sulfated polysaccharide. Dextran sulfate sodium salt has antiviral, antibacterial, anti-inflammatory, antifibrotic, and wound-healing properties. Dextran sulfate sodium salt can be used as an additive in cell culture media for preventing cell aggregation and in cosmetics as a gel-forming agent.
    Dextran sulfate sodium salt (MW>500000)
  • HY-116282W
    Dextran sulfate sodium salt (MW 6500-10000) 9011-18-1 98%
    Dextran sulfate sodium salt (DSS) (MW 6500-10000) is a polymer of dehydrated glucose with a molecular weight of approximately 5000. Dextran sulfate sodium salt with different molecular weights exhibits different biological activities. Dextran sulfate sodium salt (MW 6500-10000) has antiviral activity against HIV-1 and HIV-2. Dextran sulfate sodium salt (MW 6500-10000) blocks the binding of virions to CD4⁺ T lymphocytes and inhibits syncytia formation. Dextran sulfate sodium salt (MW 6500-10000) also prevents experimental urolithiasis due to its cytoprotective actions. Moreover, because of its biocompatible and highly charged properties, Dextran sulfate sodium salt (MW 6500-10000) is a suitable choice for pharmaceutical systems.
    Dextran sulfate sodium salt (MW 6500-10000)
  • HY-116374R
    Glycolithocholic acid (Standard) 474-74-8 99.81%
    Glycolithocholic acid (Standard) is the analytical standard of Glycolithocholic acid. This product is intended for research and analytical applications. Glycolithocholic acid (Lithocholylglycine), an endogenous metabolite, is a glycine-conjugated secondary bile acid. Glycolithocholic acid can be used to diagnose ulcerative colitis (UC), non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC).
    Glycolithocholic acid (Standard)
  • HY-116429A
    7(S)-Maresin 1 1268720-66-6 98%
    7(S)-Maresin 1 is an inactive 7(S) exomer of Maresin 1, containing a 7(R) hydroxyl group. It can be used as a negative control. Maresin 1 is a specific regulator of endogenous DHA production in the human body, which can stimulate the production and secretion of intracellular Ca2+.
    7(S)-Maresin 1
  • HY-116429S
    Maresin 1-d5 98%
    Maresin 1-d5 is the deuterium labeled Maresin 1. Maresin 1, produced by human Mφs from endogenous docosahexaenoic acid (DHA) and a specialized proresolving mediator, stimulates intracellular [Ca2+] and secretion. Maresin 1 possesses anti-inflammatory activity.
    Maresin 1-d5
  • HY-116444A
    16-HETE 128914-46-5 98%
    16-HETE is arachidonic acid metabolite through subterminal hydroxylation by cytochrome P-450. 16-HETE exhibits vasodilatory and PMN inhibitory effects and serves as biomarker for early stages of non-alcoholic fatty liver disease.
    16-HETE
  • HY-116807R
    Dihydrolipoic Acid (Standard) 462-20-4
    Dihydrolipoic Acid (Standard) is the analytical standard of Dihydrolipoic Acid. This product is intended for research and analytical applications. Dihydrolipoic Acid (DHLA) is an excellent antioxidant capable of scavenging almost any oxygen-centered radical. Dihydrolipoic acid exhibits anti-inflammatory properties in various diseases. Dihydrolipoic Acid exerts a preventive effect via ERK/Nrf2/HO-1/ROS/NLRP3 pathway in LPS-induced sickness behavior rats. Dihydrolipoic Acid can be used for the reaserch of depression.
    Dihydrolipoic Acid (Standard)
  • HY-117275A
    Meclofenamic acid sodium hydrate 67254-91-5 98%
    Meclofenamic acid (Meclofenamate) sodium hydrate is a non-steroidal anti-inflammatory agent. Meclofenamic acid sodium hydrate is a highly selective FTO (fat mass and obesity-associated) enzyme inhibitor. Meclofenamic acid sodium hydrate competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid sodium hydrate is a non-selective gap-junction blocker. Meclofenamic acid sodium hydrate inhibits hKv2.1 and hKv1.1, with IC50 values of 56.0 and 155.9 μM, respectively.
    Meclofenamic acid sodium hydrate
  • HY-117275R
    Meclofenamic acid (Standard) 644-62-2
    Meclofenamic acid (Standard) is the analytical standard of Meclofenamic acid. This product is intended for research and analytical applications. Meclofenamic acid (Meclofenamate) is a non-steroidal anti-inflammatory agent. Meclofenamic acid is a highly selective FTO (fat mass and obesity-associated) enzyme inhibitor. Meclofenamic acid competes with FTO binding for the m(6)A-containing nucleic acid. Meclofenamic acid is a non-selective gap-junction blocker. Meclofenamic acid inhibits hKv2.1 and hKv1.1, with IC50 values of 56.0 and 155.9 μM, respectively.
    Meclofenamic acid (Standard)
  • HY-117287A
    Deucravacitinib hydrochloride 1609392-28-0 98%
    Deucravacitinib hydrochloride (BMS-986165 hydrochloride) is a highly selective all-site inhibitor with potent inhibitory activity against TYK2. Deucravacitinib hydrochloride can effectively block IL-12, IL-23 and type I interferon signaling. Deucravacitinib hydrochloride demonstrates significant efficacy in preclinical models of inflammatory bowel disease. Deucravacitinib hydrochloride demonstrated superiority over placebo and apremilast on multiple efficacy endpoints in moderate to severe plaque psoriasis. Deucravacitinib hydrochloride was well tolerated in inhibition.
    Deucravacitinib hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity